Actively Recruiting
Study to Assess Effectiveness and Safety of Zanubrutinib for Patients With Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)
Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2025-02-12
59
Participants Needed
15
Research Sites
24 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Observational, non-interventional, retrospective, multicentre study focusing on efficacy and safety of zanubrutinib in daily clinical practice in patients with relapsed/refractory (R/R) marginal zone lymphoma.
CONDITIONS
Official Title
Study to Assess Effectiveness and Safety of Zanubrutinib for Patients With Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed diagnosis of relapsed/refractory marginal zone lymphoma
- Patients who received at least one dose of zanubrutinib under the Named patient program (D.M. 7 Sep 2017), between January 2021 and October 2023 3) Age≥18 at start of zanubrutinib therapy. 4) Signature of written informed consent to study participation and personal data processing.
You will not qualify if you...
1) relapsed/refractory marginal zone lymphoma patients who received zanubrutinib in a clinical trial context.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 15 locations
1
AOU SS Antonio e Biagio e Cesare Arrigo
Alessandria, Alessandria, Italy, 15121
Not Yet Recruiting
2
IRCCS-AOU di Bologna
Bologna, Bologna, Italy, 40138
Not Yet Recruiting
3
P.O. Garibaldi-Nesima_UOC Ematologia
Catania, Catania, Italy, 95122
Not Yet Recruiting
4
AO di Cosenza, P.O. "Annunziata" - UOC di Ematologia
Cosenza, Cosenza, Italy, 87100
Not Yet Recruiting
5
AOU di Ferrara_ UO di Ematologia - Dipartimento di Oncologia e Medicine Specialistiche
Ferrara, Ferrara, Italy, 44124
Not Yet Recruiting
6
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS
Meldola, Forlì Cesena, Italy, 47017
Actively Recruiting
7
Istituto Clinico Humanitas IRCCS - UO Ematologia
Milan, Milano, Italy, 20089
Not Yet Recruiting
8
ASST Grande Ospedale Metropolitano Niguarda _ UOC Ematologia
Milan, MIlano, Italy, 20162
Not Yet Recruiting
9
IOV - Istituto Oncologico Veneto - IRCCS _UOC Oncologia1
Padova, Padova, Italy, 35128
Not Yet Recruiting
10
Ospedali Riuniti Villa Sofia - Cervello _ UO di Ematologia ad Indirizzo Oncologico
Palermo, Palermo, Italy, 90146
Not Yet Recruiting
11
Ospedale Santa Maria delle Croci- OU Ematologia di Ravenna
Ravenna, Ravenna, Italy, 48121
Not Yet Recruiting
12
Fondazione PTV Policlinico Tor Vergata- U.O.C. Patologie Linfoproliferative
Roma, Roma, Italy, 00133
Not Yet Recruiting
13
AOU Città della Salute e della Scienza, "Le Molinette" - Divisione di Ematologia
Torino, Torino, Italy, 10126
Not Yet Recruiting
14
Ospedale Ca' Foncello, Azienda ULSS n. 2 Marca trevigiana - UOC Ematologia Dipartimento di Medicina
Treviso, Treviso, Italy, 31100
Not Yet Recruiting
15
Azienda sanitaria universitaria Giuliano Isontina (ASU GI) - Ospedale Maggiore- SC (UCO) Ematologia
Trieste, Trieste, Italy, 34128
Not Yet Recruiting
Research Team
P
Pier Luigi Zinzani, MD
CONTACT
A
Alessandro Broccoli, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here